Skeletal outcomes and SRE according to time of bone metastases appearance.

<p>SRE, skeletal-related event.</p

Predictive factors of time of bone metastases diagnosis: multivariate analysis.

<p><i>P</i> determined by Cox proportional hazards model.</p

Median time to bone metastases diagnosis: univariate analysis.

a<p>At time of diagnosis; CI, confidence interval; <i>P</i> determined by Log-rank test; SRE, skeletal-related event.</p

Patients survival parameters according bone metastasis onset.

<p>CI, confidence interval; SRE, skeletal-related event.</p

Percentage of skeletal-related events (SREs) occurring in patients with bone metastases from gastric cancer.

<p>Percentage of skeletal-related events (SREs) occurring in patients with bone metastases from gastric cancer.</p

Median survival after bone metastases diagnosis: univariate analysis.

<p>CI, confidence interval; <i>P</i> determined by Log-rank test; SRE, skeletal-related event.</p

Patient bone disease characteristics in the entire population.

a<p>Included first, second and third; SRE, skeletal-related event.</p

Predictive factors of survival after bone metastases diagnosis: multivariate analysis.

<p>P determined by Cox proportional hazards model.</p

Comparison of time to first SRE in patients receiving zoledronic acid before SRE (n = 31) and those who did not receive zoledronic acid (n = 85, p = 0.0005).

<p>Data are presented as mean ± SEM Statistical significance was determined by Mann-Whitney test.</p